Aim: To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add-on to sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy.
like peptide-1 receptor agonist (GLP-1RA) or sodium-glucose cotransporter-2 (SGLT2) inhibitor to basal insulin, are well established. 1, 2 IDegLira is a fixed-ratio combination of the basal insulin degludec and the GLP-1RA liraglutide; the safety and efficacy of IDegLira have been demonstrated in a variety of patient populations in the DUAL clinical trial programme. [3] [4] [5] [6] [7] [8] [9] In the DURATION-8 10 and AWARD-10 11 clinical trials, combined therapy with GLP-1RAs and SGLT2 inhibitors in patients failing to achieve glycaemic control on metformin and SGLT2
inhibitor ± metformin, respectively, resulted in improvements in glycaemic control, with no unexpected side effects. Treatments belonging to the GLP-1RA and SGLT2 inhibitor classes of medications exert their positive effects on patients by different, but complementary, modes of action. GLP-1RAs achieve reduction of glucose levels by stimulating insulin secretion and suppressing pancreatic glucagon secretion, reducing glucose output from the liver and reducing the gut-to-bloodstream glucose transfer rate by slowing gastric emptying.
Inhibition of SGLT2 protein transporters in the proximal renal tubule, which have a role in~90% of glucose reabsorption, increases urinary glucose secretion and indirectly increases glucagon concentration.
Current T2D treatment guidelines recommend the sequential addition of up to two further therapies if glucose remains uncontrolled within 3 months of metformin initiation, before initiating combination injectable therapy. 1 To determine if there are therapeutic advantages to initiating a fixed-ratio combination of a basal insulin and a GLP-1RA
as first injectable therapy, the DUAL IX study (clinicaltrials.gov:
NCT02773368) compared the efficacy and safety of IDegLira with insulin glargine 100 units/mL (IGlar U100), the most widely prescribed basal insulin worldwide and common next-step in care, 12, 13 as an addon to SGLT2 inhibitor therapy in insulin-naïve people with T2D inadequately controlled on SGLT2 inhibitors, in combination with other oral antidiabetic drugs (OADs). sation Good Clinical Practice 14 and the Declaration of Helsinki. 15 The 32-week trial comprised a 2-week screening period, a 26-week treatment period, and two follow-up safety assessments at 7 (+3) days and 30 days (+3 days) after last dose of randomized treatment. An interactive web response system was used to randomize participants 1:1 to IDegLira or IGlar U100. Existing DPP-4 inhibitor therapy was discontinued at randomization. Prior to trial initiation, the protocol, consent form, and participant information sheet were reviewed and approved according to local regulations by appropriate health authorities, and an independent ethics committee/institutional review board. Participants provided written informed consent prior to inclusion in the trial.
| MATERIALS AND METHODS

| Study design
Treatment assignment was masked for a safety committee, an independent external committee that adjudicated selected adverse events (AEs), and personnel involved in defining the analysis sets until the database was released for statistical analysis, but was not masked for patients and all other investigators.
| Participants
Participants were aged ≥18 years, and had a glycated haemoglobin (HbA1c) concentration of 53-97 mmol/mol (7.0-11.0%), a body mass index (BMI) 20-40 kg/m 2 and T2D uncontrolled on SGLT2 inhibitors ± other OADs (metformin, DPP-4 inhibitors and/or pioglitazone). Full inclusion/exclusion criteria are provided in Table S1 .
| Interventions
IDegLira and IGlar U100 were administered once daily subcutaneously, as add-on to existing therapy, both initiated at a dose of 10 units (U) and titrated twice-weekly to a fasting plasma glucose (FPG) target of 4.0-5.0 mmol/L (72-90 mg/dL) according to the titration algorithm (Table S2 ). The maximum approved IDegLira dose was 50 U; IGlar U100 had no maximum dose. IDegLira was supplied in a 3-mL pre-filled FlexTouch ® pen with a fixed insulin degludec/liraglutide ratio of 100 U/3.6 mg per mL solution. IGlar U100 (100-U/mL solution) was supplied in a 3-mL pre-filled Solostar injection pen (Sanofi, Paris, France).
| Endpoints
The primary endpoint was change in HbA1c from baseline to week 26. Confirmatory secondary endpoints consisted of change from baseline in body weight, the number of treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic episodes during the 26-week study, and total daily insulin dose at end of study. 
| Efficacy and safety analyses
The full analysis set comprised all randomized participants and the safety analysis set included all participants who received at least one dose of trial product. The primary estimand in this study was the difference at 26 weeks between participants with T2D randomized to IDegLira or IGlar U100, regardless of whether participants remained on the initially assigned treatment or not. The results for the primary estimand include retrieved data at week 26 for participants who discontinued trial product prematurely.
The primary statistical analyses were performed based on the full analysis set. The primary endpoint was first evaluated in terms of noninferiority (to a limit of 0.3%) of IDegLira versus IGlar U100. Subsequently, confirmatory secondary hypotheses tested the superiority of IDegLira versus IGlar U100 in terms of the confirmatory secondary endpoints and change from baseline in HbA1c. Family-wise type I error was controlled at 2.5% one-sided by applying a hierarchical testing approach. P values without multiplicity adjustment are considered nominal.
Continuous endpoints were assessed using analysis of covariance, with treatment, pre-trial OAD, and region as fixed factors, and the corresponding baseline value as covariate. Lipid endpoints and the corresponding baseline value were log-transformed before analysis.
Missing data were imputed by unconditional reference-based multiple imputation, 17 based on 1000 imputations and assuming an immediate loss of treatment effect in the IDegLira arm. Retrieved data were available for confirmatory analyses; participants discontinuing trial product prematurely as a result of any of the rescue criteria, criteria for premature discontinuation of trial product, or at participants' own will had to attend a visit at week 26 to report HbA1c, body weight, and total insulin dose. The imputation method and use of retrieved data in analyses can equalize treatments, and could make it easier to demonstrate non-inferiority. To mitigate this potential bias, a penalty corresponding to the non-inferiority margin was added to the imputed IDegLira values when making the non-inferiority comparison.
Hypoglycaemic endpoints were analysed using a negative binomial regression model with treatment, pre-trial OAD, region and visit as fixed factors. Missing data were imputed by multiple imputation.
Responder endpoints were analysed by logistic regression with treatment, pre-trial OAD and region as fixed factors and baseline HbA1c (and baseline body weight when body weight was part of the composite) as covariates. Missing data were predicted from unconditional reference-based multiple imputation before applying the responder criterion.
The nine-point SMBG profile was analysed jointly via a mixed model for repeated measurements with an unstructured residual covariance structure with treatment, time point, pre-trial OAD, region and interaction between treatment and time point, and the interaction between pre-trial OAD and time as fixed factors, and participant as random effect.
Sensitivity analyses were carried out for the primary and confirmatory secondary endpoints applying different assumptions for the missing data to evaluate the robustness of the results.
Post hoc analyses were performed using the same multiple imputation approach assessing the primary estimand, with the subgroup pre-trial DPP-4 inhibitor use included as an interaction term with randomized treatment.
3 | RESULTS
| Participants
In total, 554 participants were screened and 420 randomized to treatment (210 to each arm). One participant randomized to IDegLira in error (study entry criteria were not fulfilled), was withdrawn before administration of any study treatment. Participant disposition is shown in Figure S1 . The rate of withdrawals was 4.8% (n = 10) for IDegLira and 1.9% (n = 4) for IGlar U100, with no obvious clustering of reason for withdrawal.
Baseline characteristics were similar for the two treatment arms (Table 1 ). All SGLT2 inhibitors marketed at study initialization were allowed in this study, the distribution at baseline being 44.5%, 34.8% and 20.5% for dapagliflozin, empagliflozin and canagliflozin, respectively.
| Primary endpoint
The mean HbA1c reductions from baseline to end of trial were 21 mmol/mol (1.9%-points) with IDegLira and 18 mmol/mol (1.7%-points) with IGlar U100 ( Figure 1A ). Non-inferiority of IDegLira versus IGlar U100 was confirmed (P < 0.0001). Superiority for IDegLira versus IGlar U100 for change in HbA1c was also confirmed with an estimated treatment difference (ETD) of For both treatments, the mean total daily insulin dose gradually increased over the first 12 weeks of the study before stabilizing for
IDegLira and continuing to increase, by~1 U/week on average from week 12 to end of trial, for IGlar U100 ( Figure 1D ). The mean (SD) total daily insulin dose at end of study was 36.2 (13.4) U for IDegLira and 53.5 (26.1) U for IGlar U100, an ETD of −15.37 U (95% CI -19.60, −11.13; P < 0.0001), confirming superiority of IDegLira. By week 26,~30% of participants were on the maximum permitted IDegLira dose, 83% of these participants reached the target of HbA1c <53 mmol/mol (<7%).
| Supportive secondary endpoints
A more rapid decline in FPG level was seen with IDegLira versus IGlar U100 ( Figure 1E Both treatments were titrated according to the same algorithm (Table S2) There were no statistically significant differences between treatments in any of the assessments of fasting lipid levels (Table S3) .
Results for the TRIM-D PRO questionnaire demonstrated significantly greater improvements for IDegLira, versus IGlar U100, for total TRIM-D score (P = 0.0052) and the "treatment burden" (P = 0.0414) and "diabetes management" (P < 0.0001) domains. The greatest improvement for IDegLira versus IGlar U100 was observed in the diabetes management domain (change in score from baseline of 17.4 and 9.3, respectively). Abbreviations: BMI, body mass index; DPP-4, dipeptidyl peptidase-4; HbA1c, glycated haemoglobin; IDegLira, insulin degludec/liraglutide; IGlar U100, insulin glargine 100 units/mL; n, number of patients; OAD, oral antidiabetic drug; SGLT2, sodium-glucose co-transporter-2. Data are mean (SD) unless otherwise stated. Baseline refers to week 0. The duration of diabetes is calculated as the time from date of diagnosis to the randomization date. DPP-4 inhibitor therapy was discontinued at randomization. Mean observed values with error bars (standard error of the mean) based on full analysis set. 26 †: estimated mean values and the corresponding error bars at week 26 with missing data derived using unconditional reference based multiple imputation. The response and change from baseline in response after 26 weeks for glycated haemoglobin (HbA1c) and body weight are assessed using an analysis of covariance (ANCOVA) model with treatment, pre-trial oral antidiabetic drug (OAD) and region as factors and corresponding baseline value as covariate. Data obtained after premature treatment discontinuation are included in the analysis. Number of treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic episodes are analysed using a negative binomial regression model with a log link and the logarithm of the exposure time as offset. The model includes treatment and pre-trial OAD as fixed factors. Missing data are imputed using multiple imputation (conditioning on expected event rate before premature treatment discontinuation or withdrawal from trial as if treated with IGlar U100). The actual daily total insulin dose after 26 weeks is analysed using an ANCOVA model with treatment, pre-trial OAD and region as factors and baseline HbA1c as covariate. Data obtained after premature treatment discontinuation are included in the analysis. Missing data are imputed using unconditional reference based on multiple imputation. CI, confidence interval; ETD, estimated treatment difference; FPG, fasting plasma glucose; IDegLira, insulin degludec/liraglutide; IGlar U100, insulin glargine 100 units/mL; N, number of patients
| Safety outcomes
The overall TEAE rates were numerically higher with IDegLira than IGlar U100 (Table 3) , mainly as a result of higher rates with IDegLira for increased lipase (Table S4) gets. 21 Weight gain and hypoglycaemia are well-known barriers for insulin initiation for both patients and healthcare providers, 22 therefore IDegLira should be considered at the point of insulin initiation, as 
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Abbreviations: ANCOVA; analysis of covariance; CI, confidence interval; ETD, estimated treatment difference; IDegLira, insulin degludec/liraglutide; IGlar U100, insulin glargine 100 units/mL; n, number of patients; OAD, oral antidiabetic drug; SMBG, self-measured blood glucose. Data are mean (SD). SMBG assessed with glucose meter as plasma equivalent values of capillary whole blood glucose, the mean profile value is defined as the area under the profile divided by measurement time and is calculated using the trapezoidal method. The response and change from baseline in response are analysed using an ANCOVA model with treatment, pre-trial OAD and region as factors and corresponding baseline value as covariate. Missing data were imputed by unconditional reference based multiple imputation.
patients will have the potential benefits of superior glycaemic control, with lower weight gain and a lower risk of hypoglycaemia, as well as lower perceived treatment burden and easier diabetes management, which could improve treatment compliance and satisfaction. inhibitors at baseline found no differences in the glycaemic variables.
In conclusion, in people who were inadequately controlled on SGLT2 inhibitor and up to three other OADs, initiation of IDegLira was superior to IGlar U100 in terms of glycaemic control, body weight, hypoglycaemia and total daily insulin dose. There were no Abbreviations: AE, adverse event; CV, cardiovascular; E, number of adverse events; EAC, Event Adjudication Committee; MACE, major adverse cardiovascular events, n, number of patients with one or more event; PYE, participant-years of exposure (1 PYE = 365.25 days); R, rate (number of adverse events divided by patient-years of exposure multiplied by 100).
a The event was a major CV event (CV death), following a myocardial infarction that occurred >7 days but <30 days after the last day of randomized treatment, therefore the myocardial infarction was not regarded as a treatment-emergent AE but the subsequent CV death met criteria for treatment-emergent MACE. Treatment-emergent: onset date on or after the first day of exposure to randomized treatment and no later than 7 days after the last day of randomized treatment. %, percentage of participants with one or more events.
